drugset / Trial / NCT07699770

Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial

NCT07699770

Phase 4 Not yet recruiting 110 enrolled Tang-Du Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.

Timeline

Start
2026-06-15
Primary completion
2027-10-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK16149 Unknown 20 mg
Subject HSK16149 Unknown 40 mg